Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer - PubMed (original) (raw)
Comparative Study
doi: 10.1245/s10434-008-9971-5. Epub 2008 Jun 3.
Moritz Koch, Daniel Nummer, Sylvia Palm, Luis Galindo, Daniel Autenrieth, Nuh Rahbari, Friedrich H Schmitz-Winnenthal, Volker Schirrmacher, Markus W Büchler, Philipp Beckhove, Jürgen Weitz
Affiliations
- PMID: 18521684
- DOI: 10.1245/s10434-008-9971-5
Comparative Study
Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
Philipp Wagner et al. Ann Surg Oncol. 2008 Aug.
Erratum in
- Ann Surg Oncol. 2009 Apr;16(4):1084. Rahbari, Nuh [added]
Abstract
Background: Tumor-infiltrating T lymphocytes (TIL) play an important role in primary colorectal cancer, but their activity in liver metastases has not yet been investigated. The aim of this study was to examine whether tumor-selective infiltration, activation, and cytotoxic activity of TIL can be demonstrated in situ in colorectal liver metastases.
Methods: TIL were obtained from liver metastases and corresponding normal liver tissue of 16 patients with colorectal liver metastases. Characterization of TIL in situ was performed by multicolor flowcytometric analysis. Presence of tumor antigen-reactive T cells was evaluated by interferon gamma Elispot analysis.
Results: TIL in colorectal liver metastases responding against tumor antigens were present in most patients. Although the proportions of CD3(+) T cells were comparable in liver metastasis and normal liver tissue, metastases contained significantly enhanced proportions of CD4(+) cells (49% vs. 22%, P < .001). Among all CD4(+) T helper cells, the proportion of activated (CD4(+)CD25(+)) effector cells was significantly increased in liver metastases (15.0% vs. 7.8%, P = .003). Metastases showed significantly higher proportions of activated (CD69(+) [70.1% vs. 49.8%, P = .02] and CD25(+) [4.1% vs. .6%, P = .06]) and cytotoxically active (CD107a(+)) CD8(+) TIL (3.2% vs. 1.3%, P = .03). Importantly, the presence of activated T helper cells correlated with the frequencies of cytotoxic T lymphocytes that exerted cytotoxic activity in situ (P = .02).
Conclusion: CD4(+) and CD8(+) TIL are selectively activated in liver metastases, and cytotoxic T lymphocytes exert tumor-selective cytotoxic activity in situ in the presence of activated T helper cells, suggesting the requirement of in-situ-activated T helper cells for efficient cytotoxic T lymphocytes effector function.
Similar articles
- Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.
Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P, Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schirrmacher V, Büchler MW, Weitz J. Koch M, et al. Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3. doi: 10.1097/01.sla.0000247058.43243.7b. Ann Surg. 2006. PMID: 17122624 Free PMC article. - Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. Gulubova M, et al. APMIS. 2009 Dec;117(12):870-9. doi: 10.1111/j.1600-0463.2009.02547.x. APMIS. 2009. PMID: 20078551 - Dominance of CD4+ alpha/beta T-cells and inferior role of innate immune reaction in liver metastases.
Kasper HU, Drebber U, Zur Hausen A, Stippel D, Dienes HP, Dries V. Kasper HU, et al. Anticancer Res. 2003 Jul-Aug;23(4):3175-81. Anticancer Res. 2003. PMID: 12926051 - Active specific immunotherapy in hepatic metastasis.
Schlag PM, Milleck J, Liebrich W. Schlag PM, et al. Ann Ital Chir. 1996 Nov-Dec;67(6):783-91. Ann Ital Chir. 1996. PMID: 9125691 Review. - The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.
Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. Curtis NJ, et al. Eur J Surg Oncol. 2012 Oct;38(10):889-96. doi: 10.1016/j.ejso.2012.05.011. Epub 2012 Jun 19. Eur J Surg Oncol. 2012. PMID: 22721580 Review.
Cited by
- The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.
de Vries NL, Swets M, Vahrmeijer AL, Hokland M, Kuppen PJ. de Vries NL, et al. Int J Mol Sci. 2016 Jun 29;17(7):1030. doi: 10.3390/ijms17071030. Int J Mol Sci. 2016. PMID: 27367680 Free PMC article. Review. - The prognostic value of liver tumor T cell infiltrates.
Khan H, Pillarisetty VG, Katz SC. Khan H, et al. J Surg Res. 2014 Sep;191(1):189-95. doi: 10.1016/j.jss.2014.06.001. Epub 2014 Jun 7. J Surg Res. 2014. PMID: 25033707 Free PMC article. Review. - Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, Drijfhout JW, Sherlock D, Hawkins RE, Stern PL. Elkord E, et al. Cancer Immunol Immunother. 2009 Oct;58(10):1657-67. doi: 10.1007/s00262-009-0674-y. Epub 2009 Feb 17. Cancer Immunol Immunother. 2009. PMID: 19221742 Free PMC article. - Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting.
Wang Z, Ahmed S, Labib M, Wang H, Hu X, Wei J, Yao Y, Moffat J, Sargent EH, Kelley SO. Wang Z, et al. Nat Biomed Eng. 2022 Feb;6(2):108-117. doi: 10.1038/s41551-021-00820-y. Epub 2022 Jan 27. Nat Biomed Eng. 2022. PMID: 35087171 - HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases.
Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP. Katz SC, et al. Cancer Gene Ther. 2020 May;27(5):341-355. doi: 10.1038/s41417-019-0104-z. Epub 2019 Jun 3. Cancer Gene Ther. 2020. PMID: 31155611 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials